← Back to Screener
Apollomics Inc. Warrant (APLMW)
Price$0.01
Favorite Metrics
Price vs S&P 500 (26W)-47.83%
Price vs S&P 500 (4W)-0.79%
All Metrics
Price vs S&P 500 (YTD)-46.30%
10-Day Avg Trading Volume0.00M
3-Month Avg Trading Volume0.00M
52-Week Price Return-43.85%
52-Week High$0.03
26-Week Price Return-43.85%
13-Week Price Return-43.85%
3-Month Return Std Dev112.84%
Price vs S&P 500 (52W)-73.68%
Year-to-Date Return-43.85%
5-Day Price Return-6.41%
Month-to-Date Return5.04%
Price vs S&P 500 (13W)-44.53%
Beta1.28x
52-Week Low$0.01
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
APLMWApollomics Inc. Warrant | — | — | — | — | $0.01 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Apollomics Inc is a clinical-stage biopharmaceutical company developing oncology therapies that target molecular pathways and enhance immune response. Its lead candidates include vebreltinib, a c-Met inhibitor for non-small cell lung cancer and other c-Met-altered tumors, and uproleselan, an E-Selectin antagonist designed for use with chemotherapy in acute myeloid leukemia.